{'fraction_non_alphanumeric': 0.01371571072319202, 'fraction_numerical': 0.0, 'mean_word_length': 6.106194690265487, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Novel treatment for immune neuropathies on the horizon

Immune neuropathies represent a heterogeneous spectrum of acute and chronic peripheral nerve disorders of autoimmune origin. Despite the current available treatment options, immune neuropathies are still associated with severe neurological deficits and poor clinical prognosis. However, during the last years, significant advances have been made in unraveling some of the underlying pathomechanisms. The exploration of novel therapeutic approaches including monoclonal antibodies and oral immunosuppressants, known from other autoimmune disorders such as multiple sclerosis, suggests new approaches to treatment. Here, we review the available clinical data as well as the scientific rationale and expected benefits and risks for these strategies.